Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis by unknown
Gopalan et al. AIDS Res Ther  (2016) 13:34 
DOI 10.1186/s12981-016-0118-7
REVIEW
Current trends and intricacies in the 
management of HIV-associated pulmonary 
tuberculosis
Narendran Gopalan, Padmapriyadarsini Chandrasekaran, Soumya Swaminathan and Srikanth Tripathy*
Abstract 
Human immunodeficiency virus (HIV) epidemic has undoubtedly increased the incidence of tuberculosis (TB) glob-
ally, posing a formidable global health challenge affecting 1.2 million cases. Pulmonary TB assumes utmost signifi-
cance in the programmatic perspective as it is readily transmissible as well as easily diagnosable. HIV complicates 
every aspect of pulmonary tuberculosis from diagnosis to treatment, demanding a different approach to effectively 
tackle both the diseases. In order to control these converging epidemics, it is important to diagnose early, initiate 
appropriate therapy for both infections, prevent transmission and administer preventive therapy. Liquid culture 
methods and nucleic acid amplification tests for TB confirmation have replaced conventional solid media, enabling 
quicker and simultaneous detection of mycobacterium and its drug sensitivity profile Unique problems posed by 
the syndemic include Acquired rifampicin resistance, drug–drug interactions, malabsorption of drugs and immune 
reconstitution inflammatory syndrome or paradoxical reaction that complicate dual and concomitant therapy. While 
the antiretroviral therapy armamentarium is constantly reinforced by discovery of newer and safer drugs every year, 
only a few drugs for anti tuberculosis treatment have successfully emerged. These include bedaquiline, delamanid 
and pretomanid which have entered phase III B trials and are also available through conditional access national 
programmes. The current guidelines by WHO to start Antiretroviral therapy irrespective of CD4+ cell count based on 
benefits cited by recent trials could go a long way in preventing various complications caused by the deadly duo. This 
review provides a consolidated gist of the advancements, concepts and updates that have emerged in the manage-
ment of HIV-associated pulmonary TB for maximizing efficacy, offering latest solutions for tackling drug–drug interac-
tions and remedial measures for immune reconstitution inflammatory syndrome.
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Background
HIV and tuberculosis (TB) have always been faithful 
comrades facilitating each other in spreading across the 
globe. According to recent World Health Organization 
(WHO) estimates, 9.6 million cases of tuberculosis (TB) 
occurred all over the world with 12 % (1.2 million) being 
co-infected with human immunodeficiency virus (HIV); 
with 37 % of these new TB cases going undiagnosed [1]. 
In the year 2014, an estimated 1.5 million had died due to 
TB with a quarter of them caused by HIV. Pulmonary TB 
is the commonest form of TB even in HIV even though it 
is more frequently associated with dissemination locally 
and systemically, when the two infections coexist. There-
fore, early diagnosis and prevention of pulmonary TB, 
with suitable chemoprophylaxis have become key com-
ponents towards achieving the end TB strategy [1].
Despite wide spread scale up of antiretroviral therapy 
(ART), only about one-third (392,000 or 77 % of the noti-
fied TB cases known to be HIV infected) were put on 
antiretroviral therapy (ART). The aim should be to com-
bine the ideal anti-tuberculosis treatment (ATT) with 
mutually compatible highly active antiretroviral therapy 
(HAART) combinations to maximize efficacy, avoiding 
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drug–drug interaction. When ART is initiated in HIV 
infected subjects, a major complication that could arise is 
the onset of ART related immune reconstitution inflam-
matory syndrome or IRIS, requiring, early detection and 
prompt treatment. These important aspects pertaining to 
diagnosis and treatment of this deadly duo is being elabo-
rated in the following paragraphs.
Diagnosis of tuberculosis in HIV infected
Latent TB infection
HIV infection is one important factor for progression to 
TB disease, mandating meticulous screening and treat-
ment for latent M. tuberculosis infection especially in TB 
prevalent countries.
Diagnosed of latent TB infection
1. Tuberculin skin test (TST) Targeted tuberculin test-
ing for LTBI forms a strategic component of TB control 
identifying high risk population prone for developing TB 
[2]. Studies have shown that TST-positive patients ben-
efit more from IPT than those who are TST negative [3]. 
Anergy, improper cold chain maintenance can give rise 
to false negative results in HIV [2]. Considering these 
limitations in resource limited set-ups, World Health 
Organization’s Guidelines Group strongly recommends 
IPT irrespective of TST for people living with HIV [3].
2. TB MPB-64 skin patch test MPB-64 is a specific 
mycobacterial antigen secreted by M. tuberculosis, M. 
bovis and some strains of M. bovis used in this patch. This 
test is simple, non-invasive, does not require a laboratory 
or highly skilled personnel, unaffected by anergy in HIV-
infected individuals and becomes positive in 3–4  days 
after patch application on skin, and induration on skin 
lasts for a week. In a study in Manila, Philippines the sen-
sitivity of the transdermal Patch was 87.8 %, with an effi-
cacy of 92.9 % and a specificity of 100 % [4].
3. IFN-γ release assays (IGRA’s) These in  vitro blood 
assays based on IFN-γ production from sensitized T cells 
TB antigens like early secretory antigenic target 6 (ESAT 
6) and culture filtrate protein 10 (CFP 10), are commer-
cially available as QuantiFERON-TB QFT), Enhanced 
QuantiFERON-TB Gold assay and ELISPOT format, 
T-SPOT-TB assay] [5].
A study of asymptomatic adults from South Africa, a 
country with a high prevalence of co-infection found that 
the rates of positive ELISPOT and ELISA results did not 
vary significantly by HIV status compared to TST [6]. 
Due to the requirement of a good laboratory infrastruc-
ture and costs, the WHO’s Guidelines Group does not 
recommend IGRA to screen people living with HIV for 
eligibility to receive IPT, as IGRA does not spell out who 
will benefit most from IPT [3].
4. Blood biomarkers Studies are underway using host 
RNA gene expression from whole blood that allows for 
identification of prospective high risk individuals who 
can potentially progress to active tuberculosis disease [7].
Diagnosis of active TB disease
High clinical suspicion is required in diagnosing early 
TB disease especially in the context of advanced HIV 
due to paucity of classical symptoms. WHO guidelines 
on systematic screening for active pulmonary TB using 
syndromic evaluation, with active case finding serves a 
dual purpose, channelizing individuals for either chemo-
prophylaxis or for prompt initiation of treatment [8–10]. 
This simplified syndromic questionnaire of three symp-
toms namely cough, fever and night sweats had been 
effectively used to diagnose or rule out TB in a study 
from South East Asia [11].
a. Imaging techniques
Adding a chest X-ray or a CT scan to symptom screen-
ing not only increases the detection rate but the cost as 
well. The spectrum of radiographic manifestation of pul-
monary TB is dependent on the relative level of HIV-
related immunodeficiency and varies from normal chest 
X-ray (CXR) to full blown miliary TB [12, 13] (Fig. 1). A 
study to evaluate the utility of initial CXR in the diagnos-
tic algorithm for symptomatic HIV-infected patients with 
negative sputum smears, found that basing a diagnosis of 
pulmonary TB on initial CXR leads to over diagnosis of 
TB. CXR had a sensitivity and specificity of 72 and 57 %, 
respectively, with positive predictive value of 21  % and 
negative predictive value of 93 % in diagnosing PTB [14]. 
In addition routine abdominal ultrasonography, followed 
by abdominal CT scan in inconclusive cases, significantly 
increased the detection of abdominal TB in patients with 
advanced immunodeficiency [15].
b) Microbiology
1. Sputum Smear microscopy The most frequent and con-
ventional method of pulmonary TB detection in HIV 
co-infected persons involves examination of at least two 
sputum specimens, including one early-morning speci-
men, for acid-fast bacilli (AFB) [16]. Though the sen-
sitivity of sputum microscopy in HIV infection is low 
(43–51 %), it has the advantage of being inexpensive, rela-
tively rapid to perform, and specific in most settings. Flu-
orescence microscopy, light emitting diode microscopy, 
alternative specimen processing methods, such as con-
centration, bleach sedimentation and same-day sputum 
collection (front loading) strategies increase the sensitiv-
ity of sputum microscopy from 59 to 93  % in detecting 
pulmonary TB in HIV co-infected persons [17–19].
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2. Culture of Mycobacterium tuberculosis (M.Tb) Myco-
bacterial culture still remains the gold standard for TB 
diagnosis. The inherent weaknesses of smear micros-
copy to determine viability, drug resistance and species 
identification has made culture test indispensable. HIV 
co-infection does not affect the yield of mycobacte-
rial culture, but its growth on traditional solid medium 
like the Middlebrooks or Lowenstein-Jenson medium is 
rather slow requiring up to 6–8 weeks. Repeated sputum 
examinations for culture up to three specimens increases 
the yield by 10–17 % [16].
With increased sensitivity and reduced delays, auto-
mated liquid culture systems have replaced solid cultures, 
increasing case detection by 10 % with quicker TB diag-
nosis (detecting mycobacterial growth within 1–2 weeks), 
resulting in prompt treatment initiation. Methods cur-
rently in practice include Mycobacteria Growth Indicator 
Tube (MGIT) 960 [Becton–Dickinson Diagnostic Instru-
ments Systems] using fluorescent sensors, MB/BacT sys-
tem (Organon Teknika) using colorimetric sensors, ESP 
culture system II (Difco Laboratories, USA) using pres-
sure sensors, or redox reagents, such as Alamar blue [20–
22]. Among HIV-TB co-infected patients, MGIT was 
found to be more sensitive than culture and microscopy 
[23]. Other available techniques include bacteriophage 
based assays (FASTPlaqueTB), Luciferase reporter phage 
based test and Microscopic observation drug suscepti-
bility (MODS) assays. The latter is a low cost non-com-
mercial method for early detection of micro colonies and 
drug resistance [24, 25].
3. Molecular techniques Nucleic acid amplification tests 
(NAAT), are designed to amplify nucleic acid regions spe-
cific for M. tuberculosis complex and can be used directly 
on the clinical samples. NAAT yield rapid results, are 
highly specific with improved sensitivity compared to 
smear microscopy. These techniques can detect specific 
mutations, thus providing information on drug sensitivity 
as well.
Line probe assays (LPA), endorsed by the WHO in 
2008 for molecular detection of drug resistance uses 
a PCR/hybridization technique to distinguish mem-
bers of the M.Tb complex and simultaneously identifies 
drug-resistant strains by detecting the most common 
single nucleotide polymorphisms associated with resist-
ance [25]. LPAs are highly sensitive (≥97 %) and specific 
(≥99 %) for the detection of rifampicin resistance, alone 
or in combination with isoniazid (sensitivity  ≥90  %; 
specificity ≥99  %), on isolates of M. tuberculosis but it 
use is restricted to smear-positive sputum specimens 
only [26].
Xpert-MTB rif (GeneXpert) has currently taken 
the center stage, providing results within 2  h, with an 
increase in case detection rate of 45 % compared to smear 
microscopy and can be used in smear negative patients 
also [27]. It is a TB-specific automated, cartridge-based 
nucleic acid amplification assay, endorsed by WHO, for 
the rapid diagnosis of TB as well as early detection of 
rifampicin resistance among HIV-infected individuals 
among presumptive TB patients [27]. Xpert—Ultra is an 
improved version that has been equated to a liquid cul-
ture in its ability to detect Tuberculosis with an impro-
vised specificity to detect MT. TB as well as rifampicin 
resistance even among smear negative patients with HIV 
where the conventional Xpert—MTB rif has a lesser 
yield [28]. Loop-mediated isothermal amplification and 
Fluorescence in  situ hybridization using peptide nucleic 
acid probes, are other rapid and simplified molecu-
lar techniques using NAAT platform used to diagnose 
a b c
Fig. 1 Varying manifestations of TB in HIV. a Apparently normal CXR. b Caeseating mediastinal adenitis typical of TB. c Miliary TB
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Mycobacterial infection, with high sensitivity and speci-
ficity [29, 30].
4. Serological diagnosis of tuberculosis Serological 
tests have no role to play for detecting active TB disease 
either pulmonary or extra pulmonary TB, and have been 
banned by WHO [31].
Other diagnostic techniques
Capture ELISA test is available to detect lipoarabinoman-
nan (LAM) in urine specimens. Among hospitalized 
HIV-infected patients with suspected TB in Zimbabwe, 
the sensitivity of LAM was found to be significantly 
higher than that of Sputum smear microscopy, especially 
in advanced HIV with lower CD4 counts [32]. Bedside 
LAM-guided initiation of ATT for HIV-infected hospi-
talized patients with suspected TB was associated with 
a reduced 8-week mortality rate in a pragmatic, rand-
omized, multi-centric trial in Africa [33]. WHO has now 
recommended the detection of LAM, in urine speci-
mens in immunosuppressed HIV-infected patients as an 
adjunctive means of rapidly diagnosing active TB disease 
[34].
In-spite of all these newer TB diagnostic technologies, 
including Urinary LAM and Gene Xpert, clinical suspi-
cion and thorough screening of TB in HIV still plays a 
vital role.
Preventive therapy for TB in HIV infection
As the risk of TB developing in HIV infected individu-
als is 5–10 % every year, current WHO guidelines recom-
mend screening of all HIV-infected individuals for TB 
(intensified case finding), and if found to be un-infected, 
receive isoniazid preventive therapy (IPT) for a 6 months, 
irrespective of TST status [35, 36].
Various randomized controlled clinical trials on differ-
ent durations and multiple drug regimens have yielded 
varying results (Table 1).
A Cochrane systematic review of 12 trials, published 
in 2010 among 8578 patients demonstrated that IPT 
reduced the risk of active TB by 64 % among TST posi-
tive HIV-infected participants, but only by 14  % among 
TST negative individuals [37]. The key message from the 
review was that efficacy was similar regardless of drug 
type, regimen or duration compared to INH monotherapy 
[37]. CDC also recommended a 12-weekly regimen of 
INH and rifapentine given as DOT as an equal alternative 
to 9-months of daily self-supervised INH for treating LTBI 
in otherwise healthy patients aged ≥12 years and advised 
against use of rifampicin and pyrazinamide for 2 months 
as prophylaxis [38, 39]. Despite evidences in favour of 
preventive therapy, adoption of TB preventive therapy in 
clinical practice has been pretty slow, primarily due to the 
difficulty in ruling out active TB in HIV infection, apart 
from reluctance on part of policy makers and program 
implementers. Getahun et al. [40] suggested IPT be taken 
over by the HIV intervention programme for an effective 
implementation after thorough screening for TB.
Patient selection for IPT
In 2011, the WHO released simplified guidelines for IPT, 
using the clinical algorithm of any cough, night sweats, 
weight loss and/or fever. Similarly, house hold contacts 
of sputum smear positive pulmonary TB cases, espe-
cially children, are a good entry point for screening for 
TB and delivery of IPT [36]. A community wide survey 
among South African mine workers found that majority 
(approximately 80  %) were eligible for IPT [41]. Due to 
low specificity of symptom screening, C-reactive protein 
(CRP) that has a higher specificity for active TB has been 
incorporated into the diagnostic algorithm. A point-of-
care CRP could facilitate rapid initiation of IPT in HIV 
patients without active TB [42, 43].
IPT with antiretroviral therapy (ART)
Mortality within the first 6 months after initiating ART 
has been attributed to TB in most resource-limited set-
tings. Protection against TB is further optimized when 
IPT is combined with ART. Synergistic protection, with 
greater than 50  % reduction in TB rates, was found in 
patients who received both IPT and ART than protec-
tion afforded by either treatment alone [44, 45]. How-
ever, empirical TB treatment in  situations where it is 
difficult to diagnose subclinical TB like advanced HIV 
disease may not be of much benefit in reducing mortal-
ity [46].
Cost‑effectiveness of IPT
A randomized trial of HIV infected adults from 
India showed that IPT, 6EH increased life expec-
tancy by 0.8  months incurring $100 per individual 
while 36  months of INH extended life expectancy by 
0.2 months with an additional per person cost of $55 [47]. 
In addition, antepartum IPT for HIV-infected women, 
irrespective of CD4 count and TST status, was shown to 
have greater health benefits and more cost-effective than 
no IPT or TST-driven IPT in a study from India [48].
Brazil demonstrated that training health care work-
ers to screen HIV-infected adults with positive TST and 
providing IPT to those with latent TB infection was cost-
effective relative to the Brazilian GDP per capita [49]. 
Similarly, the trial from United States using 12-dose of 
weekly rifapentine plus isoniazid administered as directly 
observed treatment, also proved to be a cost-effective 
alternative to 9  months of daily self-administered iso-
niazid [50]. A decision-analysis model to study the cost-
effectiveness of IPT in Botswana revealed that treating 
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PLHIV who have positive TST with 36-month IPT was 
more cost effective for reducing both TB and death com-
pared with providing IPT without a TST, providing only 
6-month IPT, or expanding ART eligibility without IPT 
[51].
Drug resistance and IPT
A systematic review, assessing the effect of IPT on the 
risk of INH resistant TB, reported that IPT increases the 
risk of INH resistance by 1.45 times, whilst it was not sig-
nificant (Relative risk 1.45; 95 % confidence interval 0.85–
2.47) [52]. Though the study had a small sample size and 
analysis was restricted by incomplete testing of isolates, 
the relative risk showed a minimal increase in INH resist-
ant TB. However, clinical trials of IPT in HIV-infected 
patients in Botswana, India and South Africa with more 
defined cohorts did not show any increased risk of INH 
resistance amongst patients given IPT [53–56].
Summary
Latent TB is still a difficult diagnosis to make in the wake 
of HIV coinfection. Advances in molecular technology 
have partially replaced conventional cultures helping in 
prompt diagnosis of active TB yielding sensitivity results 
at the earliest. TB should be meticulously screened and 
INH preventive therapy for 6 months or any other equiv-
alent regimen should be started for TB-free HIV-infected 
individuals irrespective of Tuberculin Skin Testing. There 
is a need to update the knowledge and awareness of INH 
Preventive Therapy among health care workers and pol-
icy makers for rapid implementation and reap the ben-
efits as it can be easily coupled and monitored with ART 
initiation.
Treatment for HIV‑associated pulmonary TB
ATT drugs to be used
Management of pulmonary TB in HIV demands meticu-
lous monitoring as it is complicated by smear negativity 
and atypical presentation, emergence of drug resistance, 
Immune reconstitution inflammatory syndrome, drug–
drug interaction and increased pill burden [57]. The 
Standards of TB care in India (STCI) recommend a four 
drug regimen consisting of Isoniazid (INH), rifampicin, 
pyrazinamide and ethambutol given during in the inten-
sive phase of 2 months followed by INH and rifampicin 
with/without ethambutol (optional) in the next 4 months 
for treatment naive patients along with high dose pyri-
doxine and cotrimaxazole in HIV-TB coinfection [58]. 
HIV infection favours mycobacteremia and tissue inva-
sion resulting in abundance of intracellular and intermit-
tently dividing bacilli, making rifampicin indispensable 
in HIV associated TB [59]. This is despite therapeutic 
interactions with other concomitant medications notably 
HAART. Non-rifampicin regimens in HIV have been 
associated with inferior outcomes coupled with longer 
duration of therapy [60, 61]. The addition of quinolones 
in the intensive phase does not increase cure rate any 
further [62]. Interestingly, the sputum conversion rate is 
faster in HIV-PTB coinfection with effective ATT [63]. 
Studies comparing TB treatment outcomes between 
HIV infected and uninfected individuals have obviously 
shown better results in the latter group [64].
Empirical ATT even in advanced HIV has no definitive 
role to play. The A5274 study clearly demonstrated that 
even in a high TB burden population of 1368 participants 
with advanced HIV (CD4 < 50 cells/mm3), there was no 
benefit of empiric TB therapy over IPT when mortality 
rates at 48 weeks was compared [65].
Duration of TB therapy
TB treatment duration is not influenced or confounded 
by HIV infection currently being 6  months for Pulmo-
nary and extended in severe forms of extra pulmonary 
TB like bone and neurological TB. Centre for Disease 
Control, Atlanta recommends extension of ATT beyond 
6  months in HIV-coinfected pulmonary TB patients in 
specific instances like delayed sputum conversion or poor 
clinical improvement with/without evidence of dissemi-
nation, low CD4 count at nadir and presence of cavita-
tion [66]. Swaminathan et al. [67] compared a 6 months 
standard intermittent therapy with a 9  months regimen 
(an extended continuation phase of 3 months) in the pre-
HAART era among HIV infected pulmonary TB patients, 
and found that the favourable outcomes, failures at the 
end of treatment, adverse events and mortality (during 
treatment and follow-up of 24 months) to TB were simi-
lar. However, there was a significant reduction in bacteri-
ologically confirmed recurrences when a longer regimen 
was used. The meta-analysis by Menzies et al. [68] dem-
onstrated that extended treatment beyond 6 months (to 
8  months) did not appreciably increase the efficacy fur-
ther, justifying the current duration of 6  months. The 
same meta-analysis found only a single study having a 
higher risk of relapse with extensive cavitary disease 
demanding 8  months treatment. Hence, the authors, 
concluded that high risk identification would not be easy 
in the public health perspective that makes generalized 
extension of regimen in all cases unnecessary [68].
Dosing schedule
The legacy of intermittent regimens in India dates back 
to 1964 when Tuberculosis Research Centre used strep-
tomycin and INH administered twice weekly, yielding 
a cure rate of 94  % and a relapse rate of 8  % [69]. The 
popular attributes of intermittent regimens were opera-
tional feasibility, lesser cost, fewer side effects and ease 
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of supervision. The scientific basis for intermittent usage 
of ATT is based on post antibiotic effect of ATT or lag 
period [70]. Mycobacterium undergoes a lag phase in its 
growth pattern due to the influence of the post antibiotic 
effect, when bacilli fail to grow for a period of a few days 
even after removal of the exposed drug i.e. ATT [70]. 
However, newer hypotheses challenge this approach. It 
has been postulated that the ratio of peak concentration 
to minimum inhibitory concentration better correlates 
with the post antibiotic effect and contributes to sup-
pression of resistance than lag phase. The authors further 
hypothesized that asynchrony between the metabolism 
of these intermittently growing bacilli and the day of drug 
administration could facilitate emergence of drug resist-
ant mutants [71].
Swaminathan et  al. [67] study showed a higher inci-
dence of acquired rifampicin resistance (ARR) among 
failures, using thrice weekly rifampicin in HIV-PTB, 
which was unaltered by the duration of the regimen 
used. Interestingly, the meta-analysis by Menzies et  al. 
[68] did not find intermittent ATT dosing to be a cause 
of poorer outcomes unless the frequency of dosing went 
down to below thrice a week, but had only 2 % of patient 
in the meta-analysis being co-infected. However, the 
meta-analysis by Faiz khan et al. showed that the use of 
intermittent regimen in HIV, especially in the intensive 
phase, increased the risk of failures, relapses and emer-
gence of drug resistance which further intensifies in the 
wake of baseline H-resistance [72]. The study by Li et al. 
[73] showed that a daily intensive phase of ATT fol-
lowed by an intermittent continuation phase served as 
a useful alternative to a fully daily regimen. The updated 
review by Faiz khan et  al. [74] recommended use of a 
daily regimen throughout and extension of TB regimen 
to 8 months, but suggested further evaluation of data to 
make categorical conclusions. Recently, there has been a 
paradigm shift in approach to TB treatment among HIV 
in India, with the STCI recommending daily regimen for 
all HIV co-infected patients with ethambutol reinforced 
in the continuation phase (2EHRZ7/4HRE7) [58]. The 
only randomized trial of head to head comparison of 
daily vs thrice weekly ATT regimen in HIV patients with 
newly diagnosed rifampicin sensitive pulmonary TB, 
started on timely ART, showed a higher cure rate with 
daily compared to thrice weekly ATT (90 vs 76 %) but at 
the expense of higher incidence of hepatoxicity [75].
Acquired rifamycin resistance (ARR)—a unique phenomenon 
complicating HIV‑associated pulmonary TB
The greater percentage of persistors and bacillary 
mutants in an immunocompromised environment (of 
HIV coinfection) facilitates and favours emergence of 
drug resistance to ATT notably rifampicin [76]. Acquired 
rifamycin resistance (ARR) is the emergence of resist-
ance (defined as MIC > 128 µg/ml) to rifamycin among 
patients whose pretreatment isolates were sensitive. ARR 
is a rarity in HIV seronegative individuals with PTB. In a 
cohort of 1435 HIV sero-negative patients with drug sus-
ceptible PTB enrolled in various trials at the Tuberculo-
sis Research Centre, Chennai, only 4 patients developed 
rifampicin resistance irrespective of the dosing schedule 
[77].
On the contrary, ARR in the HIV co-infected had 
been reported with all types of rifamycin regimens used 
intermittently, be it once weekly rifapentine [78], twice 
weekly rifabutin [79, 80] or thrice weekly rifampicin [67]. 
Advanced stage of HIV, absence of HAART, extensive 
and/or disseminated TB, initial H-resistance, and subop-
timal drug concentrations due to malabsorption are con-
tributing factors for ARR. Increased tissue bacillary load 
in HIV, coupled with defective clearance attributed to 
subdued immune apparatus leads to selection of genomic 
mutants resistant to rifampicin, which is much more pro-
nounced in the face of baseline INH resistance [80–83]. 
The study by Narendran et al. [84] showed that HIV and 
INH resistance at baseline were significant risk factors 
associated with ARR and HAART only reduced the fre-
quency but did not offset the trend. The NCT 00933790 
trial evaluating the incidence of failures and ARR among 
co-infected with different dosing schedules of ATT and 
timely HAART showed that ARR occurred only with 
intermittent dosing [75].
Recurrences
TB recurrences can be either due to endogenous re-acti-
vation or exogenous re-infection, the relative proportions 
depending on the background incidence of TB, level of 
immune suppression, length of rifampicin-containing 
ATT and adherence to treatment [79, 85]. The propor-
tion of recurrences due to re-infection is more frequent 
in HIV positive individuals especially in countries with 
a higher TB burden than HIV-seronegative individuals 
with TB who have a true relapse [86].
Persistence of smear positivity in HIV—are they true 
failures?
The decision making based on sputum smears alone can 
often be misleading and one such situation is the phe-
nomenon of persistent sputum positivity despite regular 
treatment. A practical approach requires segregation of 
cases into patients with clinical improvement but smear 
positive or those who are truly failing therapy with per-
sistence/recrudescence of clinical symptoms or both cur-
rently the national programme in many countries has 
scaled up to detect early drug resistance using line probe 
assay and Xpert-MTB Rif at the start of TB treatment 
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that can simplify the problem [87]. Causes of true failures 
in HIV associated TB include emergence of ATT drug 
resistance, virological failure to ART, immunological dis-
cordance (lower CD4 with undetectable viral load) and 
malabsorption of drugs leading to cryptic non-adherence 
[79, 80, 82]. All of them may influence smear and cul-
ture conversion with the risk of subsequent failures or 
recurrences and transmission. Mal-absorption of ATT 
drugs may cause persistence of symptoms with delayed 
clearance of organisms, providing a favourable nidus for 
emergence of drug resistant mutants [81–83].
The second group of apparent failures comprises of 
patients with clinical improvement but still have spu-
tum smears positive for AFB or have apparent deterio-
ration. The differential diagnosis of the latter includes 
IRIS [88], transient resistance or “bacillary escape” [89] 
and non-tuberculous mycobacteria mimicking TB [90]. 
Atypical mycobacteria including M. avium intracellu-
lare, M. kansasi, M. fortitium have been isolated more 
frequently in advanced stages of HIV disease when the 
CD4 is <100 cells/mm3 [90]. Nocardiosis may be misdi-
agnosed as TB due to its close resemblance to the latter 
both microscopically as well as clinically [91].
Shortening TB treatment—a myth or a reality?
Whether a shorter TB regimen can work in the face of 
HIV coinfection still remains a mystery. The RIFAQUIN 
trial tested a combination of moxifloxacin replacing 
Isoniazid in the intensive phase along with rifampicin, 
pyrazinamide and ethambutol given daily in the 
2 months intensive phase followed by high dose rifapen-
tine (900/1200) for 2  months twice weekly or 4  months 
once weekly with moxifloxacin in the continuation phase 
and compared to a standard 6 months. The study failed 
to demonstrate non-inferiority of the 4  months regi-
men over the standard 6 months regimen. However, the 
6 months regimen administered once weekly during the 
continuation phase showed comparable efficacy with bet-
ter compliance and feasibility of implementation [92]. 
An important limitation in this study was that it enrolled 
only a quarter of HIV patients, with a relatively higher 
level of CD4 (above 200 cells/mm3) that limited its gen-
eralisability to advanced stages of HIV. The OFLOTUB 
study, that used gatifloxacin replacing ethambutol, also 
could not prove the 4 months regimen to be non-inferior 
to the 6 months regimen. These findings were more evi-
dent and obvious in the South African site which had half 
of their recruited patients being co-infected with HIV 
[93]. A regimen of PA_824 along with moxifloxacin and 
pyrazinamide, the STAND trial was being evaluated as 
a non-rifampicin, non-INH alternative that could prove 
useful in drug sensitive and MDR-TB, without signifi-
cant drug interaction with ART. The study would resume 
enrolment shortly after being suspended temporarily 
[94]. A recent model had been developed that could pre-
dict efficacy of new regimens of varying durations, taking 
into account culture positive rate at 2 months and could 
spell out the recurrence rates to help investigators formu-
late shorter regimens with better efficacy [95].
Summary
A standard four drug rifampicin containing regimen 
given daily for 6  months is still the ideal regimen for 
pulmonary TB in HIV despite frantic efforts globally to 
shorten TB treatment. Ethambutol can be added in the 
continuation phase. Empirical Antituberculosis therapy 
has no role to play. Acquired rifamycin resistance is a 
unique complication in HIV-TB. Patients failing therapy 
should not only be evaluate for ATT resistance but also 
efforts taken to rule out virological failure, malabsorp-
tion and screened simultaneously for non-tuberculous 
mycobacteria.
Multidrug‑resistant (MDR) and extensively 
drug‑resistant (XDR) tuberculosis
Globally in 2014, an estimated 480,000 people devel-
oped multidrug-resistant TB (MDR-TB) with an esti-
mated 39.5  % deaths and 9.7  % harboring extensively 
drug resistant TB (XDR-TB) [1]. India, China and Russia 
contribute about 60 % of global burden. While MDR-TB 
appears not to cause infection or disease more readily 
than drug susceptible TB in the HIV infected population, 
delayed diagnosis, inadequate initial treatment, and pro-
longed infectiousness contribute to increased attack rates 
among contacts, leading to high case fatality rates among 
patients [96].
Treatment for drug resistant-TB consists of at least 
4–5 effective drugs. This includes a fluoroquinolone, a 
second line injectable agent (capreomycin, kanamycin or 
amikacin) and at least 2 agents from the remaining sec-
ond line anti-TB drug classes [cycloserine, thionamides 
(ethionamide or prothionamide), linezolid, clofazimine] 
along with add on drugs like pyrazinamide, ethambu-
tol, high dose INH, bedaquiline, delamanid, Amoxycillin 
clavulanate, para-amino salicylic acid selected prefer-
entially in the order described above [97]. The intensive 
phase can be up to 8 months with a continuation phase 
without injectable up to 20  months depending on the 
therapeutic response. WHO had also come out with a 
shortened 9–12  month regimen based on the findings 
conducted by the International Union against Tubercu-
losis and Lung Diseases and Medical Research Council, 
United Kingdom, that consisted of moxifloxacin, clofa-
zimine, prothionamide and pyrazinamide for 9  months 
reinforced with kanamycin and INH high dose in the first 
4–5  months of intensive phase. This regimen, however, 
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is approved for use in second line ATT naïve patients 
(<1 month of treatment) with DST pattern showing sen-
sitivity to both quinolone and second line aminoglycoside 
at baseline, without extra-pulmonary or disseminated 
form of TB or pregnancy complicating TB [98].
Evidence for this regimen originated from the Bang-
ladesh observational cohort study by Van Deun among 
MDR-TB patients which showed a relapse free cure rate 
of 84.5 % among 515 patients, but in a virtually HIV-free 
population [99]. The same regimen, tested in the fran-
cophone African countries, among 408 patients (that 
included HIV positive −22  %) showed a relapse free 
survival rate of 82.1 %. Although treatment success rates 
did not differ by HIV status among those who survived, 
the death rate was higher among HIV co-infected 18 % 
died, compared to 5  % in HIV-seronegative patients 
[100].
Prognosis of MDR-TB in HIV continues to be grave 
with a death rate of over 50  % once again highlighting 
the ardent need to reconstitute the fallen immunity by 
timely ART initiation [101]. Two additional factors 
which hinder TB control among drug resistant cases 
include nosocomial transmission and increased inci-
dence of drug toxicity with frequent drug interruptions 
that could worsen the prognosis [102, 103]. Both the 
conditions can lead to amplification of drug resistance 
and need to be addressed urgently. Stringent airborne 
infection control measures need to be in place as an 
effective strategy and overcrowding in hospitals mini-
mized [102]. One study, surprisingly, reported a toxic-
ity of only 7 % among 2000 patients in a study in South 
Africa elucidating the fact that it is comparable to HIV 
seronegative group [104].
XDR-TB or extensively drug resistant defined as MDR-
TB (resistance to INH and rifampicin) plus resistance to 
any fluoroquinolone and one of the second line anti-TB 
injectable agents (kanamycin, amikacin or capreomycin) 
constitutes a formidable medical challenge. Although 
the absence of rifampicin brings down the occurrence of 
drug–drug interactions significantly, therapy for XDR-TB 
is confounded by other adverse reactions like QTC pro-
longation, anemia, psychiatric effects, nephrotoxicity and 
gastrointestinal intolerance in addition to increased pill 
burden [103]. Treatment options are extremely limited 
and challenging with higher frequencies of adverse events 
and death [96]. In a recent study on long term follow-up 
of XDR-TB patients from South Africa, independent pre-
dictors of probability of net sputum culture conversion 
were no previous history of multidrug-resistant tubercu-
losis (p = 0.0007), use of clofazamine (p = 0.0069) with 
survival depending on culture conversion (p  <  0.0001), 
treatment with clofazamine (p = 0.021) and ART in HIV 
(p = 0.003) [105].
Newer TB drugs in the pipeline
Bedaquiline (BDQ), one of the newer drugs condition-
ally approved by the FDA recently, has been a useful 
adjunct in drug resistant-TB therapy, especially when 
choice is limited. It is a diarylquinoline derivative that 
inhibits the mycobacterial ATP synthetase [106]. It inhib-
its both actively replicating and non-replicating myco-
bacteria with no cross resistance to any of the first line 
drugs and quinolones. It takes 3–5  days for perception 
of its bactericidal effect and has an extremely long half-
life of 4–5 months and has to be taken along with food. 
It is administered 400 mg daily for the first 2 weeks fol-
lowed by 200 mg thrice weekly up to a total of 24 weeks. 
CYP3A4 is the major cytochrome isoenzyme that metab-
olizes bedaquiline to M2, that is mainly removed in the 
stools, with only 1–4  % excreted in urine [107]. Drug-
drug interactions occur with CYP3A4 inducers (e.g., 
rifampicin reduced bedaquiline exposure by approxi-
mately 50 %, obviating co-administration). The most fre-
quent suspected adverse reactions (>20.0  % of patients) 
during treatment with bedaquiline in the controlled tri-
als (C208 stages 1 and 2) were nausea (35.3 %), arthral-
gia (29.4 %), headache (23.5 %), hyperuricemia (22.5 %), 
and vomiting (20.6 %) [106]. The magnitude of QTcF pro-
longation, one of the potential side effects of BDQ was 
greater in patients treated concomitantly with clofazi-
mine but none of them ever developed torsade de pointes 
[108]. One novel way that is being evaluated in preclini-
cal studies to counteract the effect of Bedaquiline causing 
QTC prolongation is by adding verapamil [109]. Delama-
nid (OPC67687) 100 mg, has also entered phase IIb and 
III trials. Follow up data from trial 204 which enrolled 
481 MDR-TB patients showed a 74.5  % favourable 
response among patients using delamanid for 6  months 
or more, compared to 55 % with use of delamanid for less 
than 2  months [110]. PA-824, a nitroimidazole (along 
with moxifloxacin and pyrazinamide) proved efficacious 
and safe in the phase II b study showing a greater bacte-
ricidal activity compared to standard ATT and is used in 
the STAND trial [94, 111].
Newer TB drugs and ART and drug–drug interactions 
and therapeutic implications
Bedaquiline concentration is increased with co-admin-
istered lopinavir/ritonavir by 22 % due to reduced clear-
ance, while BDQ concentration is reduced by 50 % with 
efavirenz and these combinations are better avoided. 
Nevirapine has no interaction with BDQ and can be given 
safely [112]. Delamanid is expected not to have any clini-
cally significant interaction with EFV, NVP or boosted 
PI and can be used concomitantly, as it neither induces 
nor inhibits the CYP 450 system. PA-824 concentrations 
are reduced by both EFV and lopinavir/ritonavir being 
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35 and 17 % respectively [113]. Newer derivatives of Lin-
ezolid in the pipeline are sutezolid, AZD 5487, radezolid 
and tedizolid, which are devoid of the myelosuppressive 
side effects of the linezolid, their predecessor [114].
Antiretroviral treatment (ART) in HIV‑PTB
The influence of HIV and ART on TB outcomes
In the pre-HAART era, a number of studies have shown 
considerably lower cure rates, higher mortality and 
recurrence rates of TB after standard ATT in HIV co-
infected patients compared to sero-negative individuals 
[115–117]. The study in Spain showed an efficacy of 43 % 
in HIV infected Vs 70  % in the HIV negative TB [115]. 
Nevertheless, the study by Chaisson et al. did not reveal 
the outcomes to be different based on HIV status (87 % in 
the uninfected vs 81 % among co-infected). The median 
CD4 count of the study cohort was 475  cells/mm3 sug-
gesting that preservation of adequate immunity could 
potentially improve TB outcomes in HIV emphasizing 
the need for early ART initiation [116]. Treatment of 
TB alone in HIV-TB co-infected patients did not sub-
stantially increase CD4 count nor reduced the viral load 
[117]. This had prompted both the WHO [118] and the 
National AIDS Control Organisation, (NACO) India 
[119] to recommend ART initiation irrespective of CD4 
in HIV-TB infection. The updated systematic review 
on TB treatment in HIV by Faiz khan et  al. of which 
the authors had also contributed, showed substantial 
improvement in TB treatment outcomes, reduction in 
relapse rates, mortality and acquisition of drug resist-
ance with early ART initiation [74]. Timely ART initia-
tion undoubtedly improved TB outcomes. Comparing 
HIV-TB studies conducted at NIRT in the pre- and post-
ART era, the TB outcomes were significantly better with 
HAART co-administration (favourable response of 93 vs. 
83 %) with a reduction in all-cause mortality from 17 to 
5  % [67, 120]. Pulmonary TB patients initiating ART in 
the intensive phase had a better TB outcome (adjusted 
odds ratio 1.83 (95 % CI 1.29–2.60) compared those not 
on ART from a study from Malawi [121]. A study from 
Thailand also reflected the same trends with 43 % mor-
tality in the absence of ART compared to 7 % when co-
administered with ART [122].
The ideal ART regimen for TB co‑infected patients and newer 
options available
Tenofovir, emtricitabine/lamivudine along with efavirenz 
as a single pill once a day is most ideal [123]. That efa-
virenz can still maintain an adequate plasma despite 
co-administration with rifampicin makes it suitable for 
co-administration with rifampicin in HIV-PTB [124, 
125]. While efavirenz dose (600 vs 800 mg) and concur-
rent rifampicin administration had less clinical impact 
[126], a polymorphism in the CYP2B6 gene (G–T muta-
tion) resulted in significantly higher blood levels of the 
drug resulting in increased risk of neuro-psychiatric tox-
icity [127]. Trials have shown lower dose of EFZ (400 mg) 
to be therapeutically useful, with effective virological 
suppression but with a lesser toxicity (39 vs 48 %) at the 
same time compared to the standard 600 mg [128]. Use of 
nevirapine (available as generic fixed-drug combination) 
is not recommended routinely with rifampicin, unless 
there is a contraindication to efavirenz like pregnancy or 
psychiatric illness. However, nevirapine initiation should 
be without a “lead in” period, starting with 200 mg twice 
daily to maximize efficacy in the presence of rifampicin 
[120, 129]. Caution needs to be exercised in patients with 
a higher CD4 (>400 in males and above 250 in females) 
who are prone for fulminant hepatitis while using this 
strategy [123]. Triple NRTI regimens containing abacavir 
can be used alternatively in patients negative for HLA 
B57:01, but virological suppression is inferior especially 
when the viral load is high [130]. A quadruple NRTI regi-
men including tenofovir has been found to be as effective 
as EFV based regimen in trials of a smaller number [131]. 
Rifabutin offers greater flexibility than rifampicin and the 
modifications that are required in concomitant therapy is 
depicted in Table 2.
Recently discovered drugs in the pipeline include teno-
fovir alafenamide (GS 7340), a prodrug of tenofovir, that 
gets converted at the site of lymphoid involvement and 
liver making it more potent, with greater tissue infiltra-
tion at a dosage ten times less than the conventional 
tenofovir and is currently evaluated in phase III trials in 
a fixed dose combination. There was significant improve-
ment in estimated glomerular filtration rate, bone density 
and reduced proteinuria compared to conventional teno-
fovir disoproxil fumarate [132]. Dolutegravir has been 
shown to have a superior tolerability compared to daru-
navir in the Flamingo study [133]. The dosage of dolute-
gravir has to be doubled if concomitantly administered 
with rifampicin to 50  mg BD instead of the OD dosage 
(given with rifabutin) especially if given along with EFV 
[134]. Alternatively, dolutegravir 50  mg BD can also be 
combined with lamivudine and abacavir [123].
When to start ART after ATT initiation
Evidences from the START [135] and the TEMPRANO 
study [136] has made WHO recommend early initiation 
of ART, even in asymptomatic HIV individuals irrespec-
tive of CD4 so that Immune restoration is near complete 
with reduction in mortality due to both infective and 
non-infective causes with comparable toxicities. The 
START study which had 62 % of events attributed to TB 
showed that six participants in the immediate arm and 
20 in the deferred arm of ART had broken down with 
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TB favouring immediate ART initiation [135]. Early 
initiation of ART not only reduces mortality and mor-
bidity due to HIV and TB with faster sputum conver-
sion but also prevents IRIS secondarily [79]. The SAPIT 
trial observed 56 % lower mortality among patients who 
concomitantly started ART during TB treatment com-
pared to those who subsequently started ART after ATT 
completion [137]. The important finding that can be 
deduced from the results of both the STRIDE [138] and 
SAPIT [139] trials is that while HIV-TB patients with a 
CD4 > 50 cells/mm3 need to start ART at the earliest with 
counselling on early recognition of signs and symptoms 
of IRIS and toxicity, a permissible delay of ART ini-
tiation among patients with higher CD4 up to 12 weeks 
after starting ATT helps in reducing drug interactions 
between rifampicin and NNRTIs, cumulative drug toxici-
ties (especially hepatotoxicity), pill burden and the inci-
dence of immune reconstitution inflammatory syndrome 
without any compromise on survival or predisposition to 
newer opportunistic infections [140].
The CAMELIA study enrolling 661 patients with a 
median follow-up of 25  months reflected similar find-
ings that were deduced from patients in the lower range 
of CD4 in the SAPIT and STRIDES study. Early ART 
Table 2 Therapeutic modifications that are required while administering rifamycins and ART concomitantly [103, 177]
CYP cytochrome P450
Rifampicin (dosage-600 mg unless specified) 
interaction with ART modification and rec-
ommendation
Rifabutin (dosage-300 mg unless specified) 
interaction with ART modification and recom-
mendation
Nucleoside reverse transcriptase inhibitors 
(NRTI’s)
No dose modification required
Alternative regimens used only when NNRTI’s 
are contraindicated with VL < 100000copies/
ml [103]
Triple and quadruple NRTI regimens – caution to 
be exercised with triple regimen [178]
No dose modification required
Non-nucleoside reverse transcriptase inhibitors (NNRTI’s)
 Nevirapine Reduced by 55 % [179–182]
Not recommended routinely. If required., to 
avoid a lead in dose and start 200 mg BD [129]
No dose modification required as an alternative 
regimen with NVP
 Efavirenz Safe option, reduction only 20–25 % [183]. More 
dependent on CYP2B6 G516 G > T [184]
Preferred with rifampicin
Increase rifabutin dosage to 450–600 mg, usually 
not recommended
 Delavirdine Not recommended Not recommended
 Etravarine Reduction in NNRTI by 70–80 % [185]. Not 
recommended
Reduced by 35 % and Etravarine reduces rifabutin 
by 17 %. Same dose as rifabutin 300 mg [185]
 Rilviprine Reduction in NNRTI by 70–80 % [186]. Not 
recommended
 Doravirine Not recommended
Protease inhibitors
 Lopinavir/ritonavir Not recommended 150 mg daily




Increase Indinavir to 1000 mg thrice a day.
300 mg daily
150 mg thrice weekly
150 mg daily
Super boosting [51]
 Lopinavir 400/ritonavir 400 Not recommended due to toxicity [187–190] Super boosting not required for rifabutin
Double dosing [51]
 Lopinavir 800 mg/ritonavir 200 mg Not recommended due to toxicity [187–190] Double dosing not required for rifabutin
Integrase inhibitors
 Raltegravir [192, 193] Reduced by 60 % [191]
Increase dose of raltegravir to 800 mg BD [193]
Caution to be exercised in patients with higher 
VL
400 mg BD of raltegravir
 Dolutegravir [134] Increase to 50 mg BD of dolutegravir 25 mg BD of dolutegravir
 Elvitagravir/cobicistat Not recommended Not recommended as reduced by 67 % [194]
CCR5 Inhibitors
 Maraviroc Not recommended Not recommended
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initiation by 2 weeks post ATT reduced mortality signifi-
cantly compared to late initiation of ART at 8 weeks post 
ATT (18 vs 27 %, p = 0.0006). However, the risk of IRIS 
was 2.5 times more in the early ART group [141].
Current WHO and ART guidelines in India also rec-
ommend ART between 2 and 8 weeks of starting ATT on 
similar principles [119, 142].
Adverse reactions occur more often among HIV-
infected patients with TB on concurrent medication 
than among TB without HIV (serious ADR—27 vs 13 %), 
occurring mostly in the first 2 months of treatment [143, 
144]. Hepatoxicity is common due to shared metabolic 
pathways of anti-TB and antiretroviral drugs, alcohol-
ism, co-infection with Hepatitis B and C, IRIS hepati-
tis and obstruction by nodes at the porta hepatitis all 
predispose to liver injury [88]. Most cases present with 
transaminitis which resolves when drugs are withheld. In 
drug sensitive TB, non-hepatotoxic drugs like streptomy-
cin, ethambutol and ofloxacin should be substituted for 
TB treatment till liver functions return to normal, when 
all drugs can be re-introduced. Other adverse reactions 
include cutaneous and gastrointestinal symptoms and 
peripheral neuropathy which can occasionally be disa-
bling [88]. Lactic Acidosis can present in various ways 
and needs periodic estimation [145].
Isolated hyperbilirubinemia is very common with use 
of atazanavir but is more of a cosmetic disfigurement that 
may stigmatise the patient. Zinc sulphate supplementa-
tion may be useful in management of ATV-related HBR 
in selected patients [146].
Summary
The ideal co-administered ART regimen with ATT is a 
single pill of tenofovir (300 mg) along with emtricitabine/
lamivudine (300  mg) and efavirenz (600  mg) initiated 
between 2 and 12  weeks after ATT initiation, provided 
the patients’ CD4 cell count is above 50 cells/mm3 with 
compromise on survival, (when there is no clinical com-
pulsion). However, among patients with a CD4 of less 
than or equal to 50  cells/mm, immediate initiation of 
ART is the rule with proper counselling for IRIS and 
close monitoring for cumulative/additive toxicity that 
will help to maintain adherence
Tuberculosis immune reconstitution inflammatory 
syndrome (TB-IRIS)
Tuberculosis immune reconstitution inflammatory syn-
drome (TB-IRIS) is the paradoxical worsening of symp-
toms and signs of TB after starting ART (rarely with ATT 
itself ), despite a favorable immunological recovery and 
effective virological suppression [147]. Incidence ranges 
from 8–43  % [148]. The frequency and severity of IRIS 
depends on the degree of CD4 lymphocytopenia at nadir, 
the presence of other opportunistic infections and also 
the strategic location of the lesion. Figure 2 shows a pul-
monary TB patient with HIV who presented with IRIS 
lesions in the brain after initiating ART [149, 150]. TB-
IRIS is of two types (1) Paradoxical TB-IRIS that occurs 
in HIV-TB co-infected patients started on ATT and sub-
sequently started on ART. Paradoxical IRIS is relatively 
easy to diagnose because of its biphasic pattern of initial 
improvement with ATT followed by a latter phase “para-
doxical” deterioration after ART initiation. (2) Unmask-
ing TB-IRIS or ANTIRETROVIRAL therapy (ART) 
associated TB occurs in an asymptomatic individual 
without a prior diagnosis of TB who starts developing 
symptoms with ART initiation. This could either be sub-
clinical or undiagnosed TB [147, 151].
Predictors of IRIS—risk factors
The most consistent risk factors are very low levels of 
CD4 cell count, CD4/CD8 ratio, hemoglobin, weight, 
presence of disseminated disease, shorter ATT-ART 
time interval, extra pulmonary foci and other opportun-
istic infections at the time of ART initiation [150–152]. 
Interleukin-6 and CRP were found to be reliable predic-
tors of IRIS in a pure cohort of culture positive TB in 
HIV prospectively followed for IRIS occurrence in India. 
Evaluation of predictors from the CADRIS trial showed 
that baseline levels of vitamin D and higher D-dimer, 
Before ATT  Aer ATT and ART during IRIS episode Aer therapy for IRIS  
Fig. 2 Pontine abscess as a manifestation of paradoxical TB-IRIS in a patients with HIV (& hemiparesis)
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Interferon gamma (IFN-γ), and sCD14 were indepen-
dently associated with risk of IRIS [153]. TNFA-308*2 
and IL-6174G gene polymorphisms have been implicated 
in TB-IRIS causation [154].
Pathogenesis of TB-IRIS
Functional restoration of immunocompetent cells (CD4) 
causing a cytokine outburst with an overriding Th1 over 
Th2 response, apart from increase in number and their 
redistribution to the site of the lesion, is the primary 
mechanism of IRIS causation [155]. The majority of para-
doxical IRIS cases occurs within the first 3 months after 
starting ART [156]. The T-regulatory cells or committed 
suppressors of the immune system are normally restored 
post ART but are functionally defective, tilting the tide 
towards an inflammatory reaction [157]. Recently, MMP-
7, a tissue matrix metallo-proteinase, has also been impli-
cated in TB-IRIS [158].
Clinical features of TB IRIS
Fever with rigor or chills (resembling malaria) is the com-
monest and consistent symptom of TB-IRIS, with lymph 
node enlargement being the commonest manifestation 
[88]. Symptoms vary in severity from localized super-
ficial lymphadenopathy and subcutaneous abscesses to 
severe forms like adult respiratory distress syndrome, 
meningitis, enlarging space occupying lesions like tuber-
culomas and viscus perforation, which can end fatally 
[151, 159]. Compressive features due to lymphadenopa-
thy include stridor due to tracheal narrowing and supe-
rior vena caval (SVC) obstruction [160]. Patients with 
abdominal TB may present with pain and diarrhea. Other 
abdominal manifestations include hepatosplenomegaly, 
psoas abscesses, splenic micro abscesses, splenic rupture, 
epididymo-orchitis, uretric compression, and acute renal 
failure [159]. Osteomyelitis, sub-cutaneous abscesses 
and thromboembolic episodes have been reported [160]. 
Radiological worsening in pulmonary TB without symp-
toms or “cryptic IRIS” has been reported among TB 
patients alone after starting ATT in the pre HIV era also 
[161].
Diagnosis of IRIS
It is important for physicians to remember that the onset 
of this syndrome is linked temporally to ART initia-
tion, ART substitution (from I line to II line suppressing 
viremia) and ART interruption followed by re-initiation 
[88]. A strong suspicion and awareness of IRIS supple-
mented by the immunological tools of CD4 T cell count 
and viral load, after ruling out toxicity and drug resist-
ance, will help clinch the diagnosis [162]. Initial work up 
of febrile episodes for infections endemic to a particular 
place like malaria, urinary tract infection, typhoid needs 
to be performed. Radiological deterioration in Chest 
skiagram is a usual accompaniment in almost all cases 
of IRIS [153]. In some instances, increase in CD4 cell 
count may not be evident [156]. A decline of viral load 
less than 0.5 log10 copies/ml compared to baseline has a 
high negative predictive value in ruling out IRIS and is a 
mandatory criterion to differentiate it from HIV disease 
progression [159, 163]. The International network for the 
study of HIV associated IRIS (INSHI) criteria can be used 
for diagnosing unmasking IRIS and paradoxical IRIS 
[147]. Lipoarabinomannan (LAM) detection serves as a 
useful index of systemic antigen burden and has proved 
to be useful as a predictive marker [164].
When IRIS occurs at an extrapulmonary location, 
appropriate investigation can be performed and tissue 
specimen obtained wherever possible, and sent for bac-
teriological staining and culture in addition to routine 
histopathology. A negative culture that succeeds a pre-
existing or baseline positive culture (that was sensitive 
to specific drug therapy) confirms the diagnosis of IRIS 
straightaway. However, this criteria of culture negativity 
cannot be applied for diagnosing unmasking IRIS or in 
paradoxical IRIS when the ATT-IRIS interval is too short. 
Hypercalcemia is a unique accompaniment of TB-IRIS, 
attributed to the calcium deposition through increased 
secretions of 1.25 dihydoxy cholecalciferol by activated 
macrophages and CD4 T cells [165].
Differential diagnosis of IRIS
Drug resistant TB is the closest mimic that requires to be 
ruled out before steroids are administered as they form 
the cornerstone of IRIS therapy currently [166]. The 
phenomenon of “fall and rise” exhibited by the acid fast 
bacilli (described by Toman) typically mimics the tempo-
ral sequence of paradoxical IRIS [70]. Steroid administra-
tion in the face of MDR-TB could spell disaster, ending 
fatally. Zidovudine induced anemia also mimics IRIS 
presenting with fever, rigor that settles after appropri-
ate modification of ART [88]. Late onset IRIS (occurring 
after 3 months of ART initiation) is not rare but re-esti-
mation of viral load is compulsory in such patients, to 
rule out ART failure and HIV progression [167]. Lym-
phoma of the Non-Hodgkins type which could occur or 
co-exist with TB in HIV may flare up after ART and ster-




Intensive screening for TB and other opportunistic infec-
tions along with INH and cotrimaxozole prophylaxis 
reduces IRIS incidence [149, 167–169]. ART initiation 
before CD4 goes down considerably could protect against 
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opportunistic infections and subsequent IRIS [148]. If a 
patient with TB has a CD4 > 50 cells/mm3, the initiation 
of ART can be delayed up to 8 weeks with close monitor-
ing that reduces toxicity and IRIS but does not compro-
mise on survival [169].
Treatment
Anti-inflammatory drugs especially steroids form the 
backbone therapy for TB-IRIS, even though non-steroidal 
anti-inflammatory agents could prove to be a useful initial 
therapy for milder and localized cases of IRIS [153, 170]. 
A dose of 0.5–2  mg/kg body weight is usually used and 
tapered in a 4–8 weeks period depending on the site and 
severity of inflammation. Premature withdrawal of ster-
oids can cause recrudescence of symptoms [153]. Severe 
forms may require parenteral steroids initially followed by 
switch to oral steroids. Thalidomide in steroid dependent 
IRIS has shown good results. [171] Maraviroc, monteleu-
kast, pentoxifylline have not been proved to be effective in 
IRIS treatment [172]. Experimental drugs for IRIS treat-
ment in the pipeline include CXCR-3 antagonists, the 
main receptor for CXCL-10 [173], IL-18 binding protein 
and IL-6 inhibitors [174, 175], anti-CD28 therapy [176] 
and drugs modulating MMP-7 activity [158].
Conclusions
HIV-associated pulmonary TB mandates a commit-
ted approach that encompasses both effective as well as 
enduring therapy originating from newer drug combina-
tions, evolving ideas and emerging concepts from clini-
cal trials globally, which if implemented in a proper and 
coordinated manner could not only save millions of lives 
but also offer a better quality of life to patients suffering 
from this coinfection.
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